Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Nonsmall Cell Lung Cancer

Abstract

This combination of gemcitabine-cisplatin-vinorelbine with lower doses of cisplatin and gemcitabine was effective and active in advanced NSCLC. The overall response rate, 1-year survival and median survival time were nearly similar to previous trials in which higher doses of these 3 drugs were used. The toxicities were more acceptable and manageable than the regimes with higher doses; therefore, we may suggest a treatment option for advanced stage NSCLC.

Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer

“…The establishment of an optimal combination regimen with newer agents is an important step to improve the clinical outcome [20,21]. Several researchers have studied the combination of Cis and other agents and reported enhanced anticancer effects in treatment of lung cancer [22–28].…”

Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer

“…This rate ranges from 4 to 36% in the literature, the median rate being 20% [6][7][8][9][10][11][12][13][14][15][16][17] . Hematological toxicities were the same, but grade 3-4 non-hematological toxicity rates were lower than reported in earlier studies [6][7][8][9][10][11][12][13][14][15][16][17] . Grade 3-4 hepatic and renal toxicities were not observed in the present study.…”

“…No patient experienced grade 4 thrombocytopenia in our study. In the literature, the rate ranges from 4% to 67%, the median rate being 15.5% [6][7][8][9][10][11][12][13][14][15][16][17] . Twenty percent of patients experienced grade 3-4 anemia in our study.…”